TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).The analyst comments "PRME announced a positive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)